Absolute neutrophil count (ANC) >= 1,200/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uL, obtained within 4 weeks prior to randomizationXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 750/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 750/uL for patients with solid tumors and known bone marrow metastatic diseaseXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 750/uL (>= 0.75 X 10^9/L), within 14 days of registrationXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1250/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ul without the use of hematopoietic growth factors (within 14 days of treatment initiation)Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 750/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count ? 1,000/microliter (uL)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 750/uL for subjects without bone marrow involvementXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 750/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1.5 K/uLXx_NEWLINE_xXAbsolute neutrophil count ? 1,000/ulXx_NEWLINE_xXAbsolute lymphocyte count >= 150/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1.5 K/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/uLXx_NEWLINE_xXObtained within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1.5 K/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1.5 K/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 1,500/uL within 28 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count >= 1.5 K/uL within 14 days prior to start of protocol therapy.Xx_NEWLINE_xXAbsolute neutrophil count ? 1.5 K/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 750/uL\r\n* The above criteria do not have to be met if the patient has bone marrow involvement of tumorXx_NEWLINE_xXLymphocyte count > 500/uLXx_NEWLINE_xXWithin 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count < 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/ulXx_NEWLINE_xXINCLUSION - TREATMENT: Absolute neutrophil count (ANC) >500/ulXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 750/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/ulXx_NEWLINE_xXAbsolute neutrophil count =< 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1.0 K/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uL within 14 days prior to first dose of protocol-indicated treatment.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000/uL.Xx_NEWLINE_xXAbsolute lymphocyte count > 100/uL.Xx_NEWLINE_xXAbsolute neutrophil count ? 500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 500 /uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.5 k/uLXx_NEWLINE_xXAbsolute neutrophil count ? 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ uL, within 2 weeks of registrationXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 750 cells/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uL (unsupported), within 14 days of registration and within 7 days of the start of treatmentXx_NEWLINE_xXAbsolute neutrophil count >= 1,500 cells/uLXx_NEWLINE_xXAbsolute neutrophil count > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uL.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000 cells/uLXx_NEWLINE_xXObtained within 14 days of the first study treatment: Lymphocyte count > 500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1.5 K/ULXx_NEWLINE_xXAbsolute neutrophil count > 1.5 K/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1 K/uL.Xx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) 1.0 x 10^9/L (1,000/uL)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/ul (prior to biopsy)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uL.Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000/uL unless disease-related (due to marrow infiltration or splenomegaly)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXWithin 28 days prior to enrollment: Absolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) of >= 1,000/uLXx_NEWLINE_xXObtained within 14 days of the first study treatment: Lymphocyte count >500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 750/uLXx_NEWLINE_xXNo more than 14 days prior to registration: Absolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXPerformed within 14 days of treatment initiation: Absolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500 uLXx_NEWLINE_xXWithin 14 days prior to cycle 1 day 1 of treatment: Absolute lymphocyte count >= 500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count > 750 cells/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ uL, within 2 weeks of registration (except where specified otherwise)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,200/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500 /uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) =< 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute lymphocyte count ? 100/uLXx_NEWLINE_xXAbsolute lymphocyte count >= 500 cells/uL (obtained within 28 days prior to first study treatment)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uL within 14 days prior to study entryXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uL (performed within 28 days of registration)Xx_NEWLINE_xXAbsolute neutrophil count >= 1200/uL performed within 7 days of treatment initiationXx_NEWLINE_xXAbsolute neutrophil count > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count > 1,500 uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXRecovery from induction therapy (absolute neutrophil count [ANC] > 200/ul, platelet count > 20,000/ul)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) < 200/ul prior to treatmentXx_NEWLINE_xXAbsolute neutrophil count >= to 1,500 /uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uL within 30 days prior to course 1 day 1 (C1D1)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) should be > 500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/ul without growth factor supportXx_NEWLINE_xXAbsolute lymphocyte count < 500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,200/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uL obtained within 14 days of first treatmentXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000 cells/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 500/ulXx_NEWLINE_xXAbsolute lymphocyte count >= 500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXARM A COHORT 1: Absolute neutrophil count >= 1,500/ulXx_NEWLINE_xXARM B COHORT 2: Absolute neutrophil count >= 1,500/ulXx_NEWLINE_xXARM B COHORT 3: Absolute neutrophil count >= 1,500/ulXx_NEWLINE_xXARM C COHORT 4: Absolute neutrophil count >= 1,500/ulXx_NEWLINE_xXAbsolute lymphocyte count (ALC) >= 500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXLymphocyte count >= 500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000/ulXx_NEWLINE_xXAbsolute lymphocyte count of >= 500/uLXx_NEWLINE_xXMust be met within 28 days of C1D1: Absolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXINCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: Absolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count > 1,000/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uL, performed within 28 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uL within 14 days of the first dose of study drugXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uL obtained no more than 28 days prior to the start of neoadjuvant endocrine therapyXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1.5 k/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) ? 750/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500 cells/uL (to be performed within 7 days prior to start of study treatment)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than 500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000 cells/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000/ulXx_NEWLINE_xXAbsolute lymphocyte count of >= 500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uL (within 2 weeks prior to radiotherapy)Xx_NEWLINE_xXAbsolute neutrophil count >= 500/ul (phase I only)Xx_NEWLINE_xXAbsolute lymphocyte count >= 500/ul (phase I only)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 /uLXx_NEWLINE_xXAbsolute neutrophil counts >= 1,500 cells per uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 500/ulXx_NEWLINE_xXAbsolute lymphocyte count >= 500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000/ulXx_NEWLINE_xXAbsolute lymphocyte count of > 500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/ulXx_NEWLINE_xXFull hematologic recovery following Auto HCT including:\r\n* Absolute neutrophil count (ANC) >1000 ul\r\n* Platelet count of >= 50,000 ul independent of transfusion for >7 daysXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ul within 7 days prior to starting treatmentXx_NEWLINE_xXAbsolute granulocyte count < 1,500/ulXx_NEWLINE_xXAbsolute granulocyte count < 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,500/uLXx_NEWLINE_xXPatients must have an absolute neutrophil count (ANC) > 1000/ul and a platelet count > 50,000/ulXx_NEWLINE_xXAbsolute neutrophil count > 1,500/uL during screening evaluationXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >/= 1,500 cells/ul without growth factor support prior to initial treatmentXx_NEWLINE_xXGranulocyte >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXTUMOR BIOPSY SEQUENCING: Absolute neutrophil count >= 1,000/uL (mcL)Xx_NEWLINE_xXTREATMENT: Absolute neutrophil count >= 1,000/uL (mcL)Xx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXNeutrophil count >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,500/uLXx_NEWLINE_xXSecondary Registration: absolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophils > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) > 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXLymphocyte count >= 500/uLXx_NEWLINE_xXFor patients with solid tumors and known bone marrow metastatic disease: peripheral absolute neutrophil count (ANC) >= 750/uLXx_NEWLINE_xXAbsolute neutrophil count: >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000 cells/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXGranulocyte count of at least 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXGranulocyte count >= 1,000/uL for lapatinib and > 1,500/uL for capecitabineXx_NEWLINE_xXPerformed within 14 days of patient registration: Absolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/ul without colony stimulating factor supportXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/ulXx_NEWLINE_xXAbsolute neutrophil count: >=1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uL unless due to bone marrow involvementXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute lymphocyte count >= 500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,500/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 750/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 750/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) should be > 500/uLXx_NEWLINE_xXWithin 14 days prior to registration: absolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uL obtained =< 7 days prior to randomizationXx_NEWLINE_xXAbsolute neutrophil count >= 1.0 K/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXWithin 4 weeks of administration of study therapy: Absolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 750 /uL obtained =< 7 days prior to registrationXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1,000/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 750 cells/uL within 14 days before enrollmentXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/ulXx_NEWLINE_xXAT THE TIME OF INFUSION: Absolute neutrophil count (ANC) > 750/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count < 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAdequate bone marrow function (Absolute neutrophil count (ANC) ? 1,500 cells/uL; Platelets (PLT) ? 100,000 cells/uL)Xx_NEWLINE_xXThe peripheral absolute neutrophil count must be at least 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,200/ulXx_NEWLINE_xXNeutropenia (absolute neutrophil count < 1 x 10^3/uL)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 750 cells/uL (0.75 x 10^9/L)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1.5 K/ULXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 750/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) of less than 250 cells/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 750/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count < 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 500/ulXx_NEWLINE_xXAbsolute lymphocyte count >= 500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500 cells per uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ul (unless due to bone marrow infiltration by tumor in which case ANC >= 500/ml are allowed)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1,500 /uLXx_NEWLINE_xXObtained within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXWithin 14 days after subjects signed the treatment consent: Absolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXNeutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uL, within 14 days of registrationXx_NEWLINE_xXAbsolute neutrophil count >= 1.5/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXPatients must have an absolute neutrophil count (ANC) >= 500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXWithin 14 days prior to enrollment/randomization: Absolute neutrophil count (ANC) > 1.5 K/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1.0 K/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500 cells/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count > 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ul (unless low ANC is due to multiple myeloma)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) =< 1,500 cells/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000 cells/ulXx_NEWLINE_xXNeutropenia (absolute neutrophil count < 1 x 10^3/uL)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 750 cells/uLXx_NEWLINE_xXAbsolute neutrophil count 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute lymphocyte count > 500/uLXx_NEWLINE_xXAbsolute neutrophil count > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1.0 K/uL (growth factor support is permissible)Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC): >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000/ ul 3Xx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) >= 750/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/ulXx_NEWLINE_xXAbsolute neutrophil count >= 1.0 x 10^3/uL obtained at baseline (day 1 of cycle 1, before study drug administration)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,500 cells/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1.5 K/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1200/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,500 cells/ul within 14 days prior to treatment initiationXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/ulXx_NEWLINE_xXPeripheral absolute neutrophil count (ANC) > 1,000/ulXx_NEWLINE_xXAbnormal marrow function as defined as absolute neutrophil count <1,500/ul or platelets <100,000/ul.Xx_NEWLINE_xXAbsolute neutrophil count > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 500/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > l500/ulXx_NEWLINE_xXAbsolute neutrophil count > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXPatients with absolute neutrophil count (ANC) >= 1,000/uL; the most recent ANC level taken within 60 days prior to study enrollment will be consideredXx_NEWLINE_xXHave documented lab work with absolute neutrophil count (ANC) >= 1.0 K/uL and platelets >= 50 K/uL in the past 12 monthsXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) > 1,000 cells/ulXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 500/ul without growth factor or transfusional supportXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1,500 K/UL in the past 30 daysXx_NEWLINE_xXAbsolute neutrophil count (ANC) greater than 500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) < 1,500 K/UL in the past 30 daysXx_NEWLINE_xXNeutropenia (serum absolute neutrophil count [ANC] < 1,000/uL)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXNeutrophil count >= 1,200/mm^3 (>= 1.2 k/uL)Xx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uL, obtained within 14 days prior to treatment startXx_NEWLINE_xXWithin 30 days of eligibility confirmation: Absolute neutrophil count (ANC) >= 1,500 uLXx_NEWLINE_xXObtained within 28 days prior to registration: Absolute lymphocyte count >= 500 cells/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXExisting major organ dysfunction > grade 2, with the exception of myelosuppression (neutrophil count >= 500/ul and platelet count >= 25,000/ul are acceptable) and hearing lossXx_NEWLINE_xXLymphocyte count >= 500/uLXx_NEWLINE_xXAbsolute neutrophil count > 1,000/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count > 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count >= 1,500/uLXx_NEWLINE_xXAbsolute neutrophil count (ANC) ? 750/uLXx_NEWLINE_xX